Prescription Trends in Complex Regional Pain Syndrome: A Retrospective Case-Control Study

Overview

Journal Brain Sci

Publisher MDPI

Date 2023 Jul 29

PMID 37508943

Authors

Suzanna Shermon

Kimberly M Fazio

Richard Shim

Alaa Abd-Elsayed

Chong H Kim

Affiliations

Soon will be listed here.

Abstract

Objective: The objective of this study was to evaluate discrepancies in prescription trends for analgesic medications in complex regional pain syndrome (CRPS) patients based on recommendations in the literature.

Design: We conducted a retrospective case-control study.

Subjects: A total of 2510 CRPS patients and 2510 demographic-matched controls participated in this study.

Methods: The SlicerDicer feature in Epic was used to find patients diagnosed with CRPS I or II between January 2010 and November 2022. An equal number of age-, gender-, and race-matched controls without a CRPS diagnosis were retracted from Epic. General and CRPS-associated prescription frequencies for the following classes were retrieved for both cases and controls: benzodiazepines, bisphosphonates, calcitonin, capsaicin, neuropathic pain medications, NSAIDs, opioids, and steroids.

Results: A total of 740 (29%) CRPS patients and 425 (17%) controls were prescribed benzodiazepines (95% CI 0.1-0.15), 154 (6.1%) CRPS patients and 52 (2.1%) controls were prescribed capsaicin (95% CI 0.03-0.05), 1837 (73%) CRPS patients and 927 (37%) controls were prescribed neuropathic pain medications (95% CI 0.05-0.34), 1769 (70%) CRPS patients and 1217 (48%) controls were prescribed opioids (95% CI 0.19-0.25), 1095 (44%) CRPS patients and 1217 (48%) controls were prescribed steroids (95% CI 0.08-0.14), and 1638 (65%) CRPS patients and 1765 (70%) controls were prescribed NSAIDs (95% CI -0.08-0.02), < 0.001 for all classes. With CRPS-associated prescriptions, (95% CI 0.05-0.16, < 0.001) more CRPS patients were prescribed opioids (N = 398, 59%) than controls (N = 327, 49%).

Conclusions: CRPS is difficult to treat with significant variance in suggested treatment modalities. Based on the results of our study, there is a divergence between some published recommendations and actual practice.

Citing Articles

Discrepancies in Aggregate Patient Data between Two Sources with Data Originating from the Same Electronic Health Record: A Case Study.

Yiu A, Stephenson G, Chow E, OConnell R Appl Clin Inform. 2025; 16(1):137-144.

PMID: 39938875 PMC: 11821296. DOI: 10.1055/a-2441-3677.

Ketamine Infusion for Complex Regional Pain Syndrome Treatment: A Narrative Review.

Kaye A, Tynes B, Johnson C, Strong B, Abbott B, Vucenovic J Curr Pain Headache Rep. 2025; 29(1):26.

PMID: 39808363 DOI: 10.1007/s11916-025-01360-9.

Incidence and treatment of complex regional pain syndrome after surgery: analysis of claims data from Germany.

Teichmuller K, Rose N, Dreiling J, Schwarzkopf D, Meissner W, Rittner H Pain Rep. 2024; 9(6):e1210.

PMID: 39574487 PMC: 11581752. DOI: 10.1097/PR9.0000000000001210.

Does Platelet-Rich Plasma Deserve a Role in Accelerating the Recovery of Reflex Sympathetic Dystrophy Following Distal Radius Fracture?.

Kulkarni R, Kulkarni S, Kulkarni R, Kulkarni R Indian J Orthop. 2024; 58(7):914-921.

PMID: 38948381 PMC: 11208391. DOI: 10.1007/s43465-024-01171-x.

References

Kingery W . A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain. 1998; 73(2):123-139. DOI: 10.1016/S0304-3959(97)00049-3. View

Manicourt D, Brasseur J, Boutsen Y, Depreseux G, Devogelaer J . Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity. Arthritis Rheum. 2004; 50(11):3690-7. DOI: 10.1002/art.20591. View

Palmer G . Complex regional pain syndrome. Aust Prescr. 2015; 38(3):82-6. PMC: 4653964. DOI: 10.18773/austprescr.2015.029. View

Harke H, Gretenkort P, Ladleif H, Rahman S, Harke O . The response of neuropathic pain and pain in complex regional pain syndrome I to carbamazepine and sustained-release morphine in patients pretreated with spinal cord stimulation: a double-blinded randomized study. Anesth Analg. 2001; 92(2):488-95. DOI: 10.1097/00000539-200102000-00039. View

Birklein F, ONeill D, Schlereth T . Complex regional pain syndrome: An optimistic perspective. Neurology. 2014; 84(1):89-96. DOI: 10.1212/WNL.0000000000001095. View

Breuer A, Mainka T, Hansel N, Maier C, Krumova E . Short-term treatment with parecoxib for complex regional pain syndrome: a randomized, placebo-controlled double-blind trial. Pain Physician. 2014; 17(2):127-37. View

Bickerstaff D, Kanis J . The use of nasal calcitonin in the treatment of post-traumatic algodystrophy. Br J Rheumatol. 1991; 30(4):291-4. DOI: 10.1093/rheumatology/30.4.291. View

Dowell D, Haegerich T, Chou R . CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. MMWR Recomm Rep. 2016; 65(1):1-49. DOI: 10.15585/mmwr.rr6501e1. View

Ge Y, Liao Q, Xu Y, Zhao Q, Wu B, Ye R . Anti-inflammatory signaling through G protein-coupled receptors. Acta Pharmacol Sin. 2020; 41(12):1531-1538. PMC: 7921558. DOI: 10.1038/s41401-020-00523-1. View

10.

Christensen K, Jensen E, Noer I . The reflex dystrophy syndrome response to treatment with systemic corticosteroids. Acta Chir Scand. 1982; 148(8):653-5. View

11.

Haddad M, Alsalem M, Saleh T, Jaffal S, Barakat N, El-Salem K . Interaction of the synthetic cannabinoid WIN55212 with tramadol on nociceptive thresholds and core body temperature in a chemotherapy-induced peripheral neuropathy pain model. Neuroreport. 2023; 34(8):441-448. DOI: 10.1097/WNR.0000000000001910. View

12.

Goebel A, Birklein F, Brunner F, Clark J, Gierthmuhlen J, Harden N . The Valencia consensus-based adaptation of the IASP complex regional pain syndrome diagnostic criteria. Pain. 2021; 162(9):2346-2348. PMC: 8374712. DOI: 10.1097/j.pain.0000000000002245. View

13.

Bruehl S . Complex regional pain syndrome. BMJ. 2015; 351:h2730. DOI: 10.1136/bmj.h2730. View

14.

Nielsen S, Lintzeris N, Bruno R, Campbell G, Larance B, Hall W . Benzodiazepine use among chronic pain patients prescribed opioids: associations with pain, physical and mental health, and health service utilization. Pain Med. 2014; 16(2):356-66. DOI: 10.1111/pme.12594. View

15.

Ott S, Maihofner C . Signs and Symptoms in 1,043 Patients with Complex Regional Pain Syndrome. J Pain. 2018; 19(6):599-611. DOI: 10.1016/j.jpain.2018.01.004. View

16.

Girtler R, Kloimstein H, Gustorff B . [Pronounced symptom deterioration in complex regional pain syndrome type II after isolated application of a highly concentrated capsaicin patch. A case report]. Schmerz. 2012; 27(1):67-71. DOI: 10.1007/s00482-012-1268-8. View

17.

Simpson D, Gazda S, Brown S, Webster L, Lu S, Tobias J . Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain. J Pain Symptom Manage. 2010; 39(6):1053-64. DOI: 10.1016/j.jpainsymman.2009.11.316. View

18.

Schwartzman R, Alexander G, Grothusen J . Pathophysiology of complex regional pain syndrome. Expert Rev Neurother. 2006; 6(5):669-81. DOI: 10.1586/14737175.6.5.669. View

19.

Watson C, Tyler K, Bickers D, Millikan L, Smith S, Coleman E . A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther. 1993; 15(3):510-26. View

20.

Adami S, Fossaluzza V, Gatti D, Fracassi E, Braga V . Bisphosphonate therapy of reflex sympathetic dystrophy syndrome. Ann Rheum Dis. 1997; 56(3):201-4. PMC: 1752343. DOI: 10.1136/ard.56.3.201. View